Литература

ЛИТЕРАТУРА [1] US Patent 6268346 B1 Jul 31, 2001 [2] Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress- organoprotection  hypothesis and beneficial effects of BPC. J Physiol (Paris) 1993; 87: 313-327. [3] Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology 2006; 14: 214-221. [4] Veljaca M, Pavic-Sladoljev D, Mildner B, et al. Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. Gut 2003; 51: A309. [5] Ruenzi M, Stolte M, Veljaca M, Oreskovic K, Peterson J. Ulcerative Colitis Study Group. A multicenter, randomized, double blind, placebo-controlled phase II study of PL 14736 enema in the treatment of mild-to-moderate ulcerative colitis. Gastroenterology 2005; 128: A584. [6] Sikiric P, Seiwerth S, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC-157. Curr. Pharm. Des. 2013, 19(1) 76-83 [7] Sikiric P, The pharmacological properties of the novel peptide BPC-157 (PL-10). Inflammopharmacology, 1999 (1) 1-14. [8] Sikiric P, Siwerth S, Grabarevic Z, et al. The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesion induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promoters and gut peptides. Life Sci 1994; 54: 63-68. [9] Sikiric P, Seiwerth, S, Grabarevic Z, et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol 1997; 332: 23-33. [10] Lovric-Bencic M, Sikiric P, at al. Doxorubicine – congestive heart failure increased bid endothelin-1 plasma concentration: reversal by amlodipine, losartan and gastric pentadecapeptide BPC157 in rat and mouse. J Parmacol Sci 2004, May; 95(1) 19-26 [11] Balenovic D, Bencic ML, at al. Inhibition of methyldigoxin – induced arrhytmias by pentadecapeptide BPC157: a relation with NO-system. Regul Pept 2009 Aug 7; 156(1-3)83-9 [12] WO 1998052973A1 [13] US Patent 6288028B1 Sep 11, 2001 [14] Boban Blagaic A, Blagaic V, Mirt M, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol 2005; 512: 173-179. [15] Sikiric P, Marovic A, Matoz W, et al. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson’s disease models in mice and gastric lesions induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydrophyridine. J Physiol (Paris) 1999; 93: 505-512. [16] Jelovac N, Sikiric P, Rucman R, et al. A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol induced supersensitivity to amphetamine. Biol Psychiatry 1998; 43: 511-519. [17] Jelovac N, Sikiric P, Rucman R, et al. Pentadecapeptide BPC157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. Eur J Pharmacol 1999; 379: 19-31. [18] Tohyama Y, Sikiric P, Diksic M. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyl-L-tryptophan autoradiographic measurements.Life Sci 2004; 76: 345-357. [19] Blagaic AB, Blagaic V, Romic Z, Sikiric P. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. Eur J Pharmacol 2004; 499: 285-290. [20] Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regul Pept 2010; 160: 26-32. [21] Boban Blagaic A, Turcic P, Blagaic V, et al. Gastric pentadecapeptide BPC 157 counteracts morphine-induced analgesia in mice. J Physiol Pharmacol 2009; 60(Suppl. 7): 177-181. [22] S. Ilic, D. Drmic, K. Zarkovic, et al. High hepatotoxic dose of paracetamol produces generalized convulsions and brain damage in rats. A counteraction with the stable gastric pentadecapeptide BPC-157 (PL14736). J Physiol Pharmacol 2010; 61(2):241-250. [23] Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157. J Orthop Res 2006; 24: 1109-1117. [24] Tkalcevic VI, Cuzic S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol 2007; 570(1-3): 212-221. [25] Hrelec M, Klicek R, Brcic L, et al. Abdominal aorta anastomosis in rats and stable gastric pentadecapeptide, prophylaxis and therapy. J Physiol Pharmacol 2009; 60(Suppl. 7): 161-165. [26] Sikiric P, Seiwerth S, Grabarevic Z, et al. Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. Life Sci 1993; 53: PL291-PL296. [27] Prkacin I, Separovic J, Aralica G, et al. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. J Physiol (Paris) 2001; 95: 315-324. [28] Ilic S, Brcic I, Mester M, et al. Over-dose insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. J Physiol Pharmacol 2009; 60(Suppl 7): 107-114. [29] Ilic S, Drmic D, et al. Pentadecapeptide BPC157 and its effects on a NSAID toxicity model: diclofenac – induced gastrointestinal, liver and encephalopathy lesions. Life Sci 2011, Mar 14, 88(11-12) 532-42. [30] J Orthop Res. 2010 Sep;28(9):1155-61. doi: 10.1002/jor.21107.Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Cerovecki T1, Bojanic IBrcic LRadic BVukoja ISeiwerth SSikiric P